Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANL NASDAQ:VCEL NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$7.97-0.1%$9.25$7.21▼$22.37$1.85B0.724.02 million shs2.50 million shsANLAdlai Nortye$9.95-9.5%$12.05$0.88▼$17.25$398M0.93138,161 shs147,125 shsVCELVericel$36.30+1.7%$34.17$28.95▼$45.97$1.85B1.12611,889 shs558,317 shsZYMEZymeworks$24.04-4.2%$25.88$11.51▼$29.75$1.76B1.15738,486 shs464,841 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.06%-0.13%-20.93%-48.21%-60.80%ANLAdlai Nortye-9.55%-16.67%-30.27%+11.67%+485.29%VCELVericel+1.71%+8.91%-1.31%+7.68%-15.91%ZYMEZymeworks-4.22%-4.34%-12.93%-0.17%+2,403,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$7.97-0.1%$9.25$7.21▼$22.37$1.85B0.724.02 million shs2.50 million shsANLAdlai Nortye$9.95-9.5%$12.05$0.88▼$17.25$398M0.93138,161 shs147,125 shsVCELVericel$36.30+1.7%$34.17$28.95▼$45.97$1.85B1.12611,889 shs558,317 shsZYMEZymeworks$24.04-4.2%$25.88$11.51▼$29.75$1.76B1.15738,486 shs464,841 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.06%-0.13%-20.93%-48.21%-60.80%ANLAdlai Nortye-9.55%-16.67%-30.27%+11.67%+485.29%VCELVericel+1.71%+8.91%-1.31%+7.68%-15.91%ZYMEZymeworks-4.22%-4.34%-12.93%-0.17%+2,403,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.20Hold$19.00138.39% UpsideANLAdlai Nortye 2.60Moderate Buy$24.25143.72% UpsideVCELVericel 2.50Moderate Buy$55.4052.62% UpsideZYMEZymeworks 2.91Moderate Buy$38.0058.07% UpsideCurrent Analyst Ratings BreakdownLatest ANL, ADMA, ZYME, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026ZYMEZymeworks HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.006/1/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/28/2026ANLAdlai Nortye OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.005/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/11/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/8/2026ZYMEZymeworks Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.005/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.62$0.65 per share12.18$2.01 per share3.97ANLAdlai Nortye$5M79.60N/AN/A($0.21) per share-47.38VCELVericel$276.26M6.71$0.56 per share65.35$7.01 per share5.18ZYMEZymeworks$105.96M16.57N/AN/A$3.59 per share6.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6811.727.59N/A32.43%39.98%28.08%8/5/2026 (Estimated)ANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)VCELVericel$16.52M$0.4286.4343.21N/A7.35%6.41%4.61%7/30/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/AN/AN/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest ANL, ADMA, ZYME, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANLAdlai NortyeN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ANLAdlai NortyeN/A0.650.65VCELVericelN/A5.184.79ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANLAdlai Nortye35.21%VCELVericelN/AZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANLAdlai NortyeN/AVCELVericel7.60%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableVCELVericel30051.07 million47.19 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/AANL, ADMA, ZYME, and VCEL HeadlinesRecent News About These CompaniesZymeworks (ZYME) Gets a Buy from Wells FargoJune 3 at 1:53 PM | theglobeandmail.comAnalyzing PyroGenesis Canada (NASDAQ:PYRGF) & Zymeworks (NASDAQ:ZYME)May 31, 2026 | americanbankingnews.comZymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC OptionalityMay 22, 2026 | seekingalpha.comVanguard Group Inc. Increases Position in Zymeworks Inc. $ZYMEMay 15, 2026 | marketbeat.comZymeworks Authorizes 2026 Share Repurchase Program, Affirms LiquidityMay 14, 2026 | tipranks.comZymeworks’ Earnings Call Balances Progress And PressureMay 14, 2026 | theglobeandmail.comZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | financialpost.comFZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)May 14, 2026 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | financialpost.comFZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZymeworks Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comHere's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comA Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return UpdatesMay 9, 2026 | finance.yahoo.comZymeworks Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comZymeworks Inc. (ZYME) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comZymeworks (NASDAQ:ZYME) Trading Down 8.9% After Earnings MissMay 8, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) StockMay 8, 2026 | marketbeat.comZymeworks (ZYME) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comZymeworks (NASDAQ:ZYME) Posts Quarterly Earnings Results, Misses Estimates By $0.49 EPSMay 7, 2026 | marketbeat.comZymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANL, ADMA, ZYME, and VCEL Company DescriptionsADMA Biologics NASDAQ:ADMA$7.97 -0.01 (-0.13%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$8.04 +0.08 (+0.94%) As of 06/5/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Adlai Nortye NASDAQ:ANL$9.95 -1.05 (-9.55%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$9.86 -0.09 (-0.95%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Vericel NASDAQ:VCEL$36.30 +0.61 (+1.71%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$36.26 -0.03 (-0.10%) As of 06/5/2026 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Zymeworks NASDAQ:ZYME$24.04 -1.06 (-4.22%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$23.16 -0.88 (-3.64%) As of 06/5/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
